Advertisement

The current status of NCI trials in Hodgkin’s disease

  • R. C. Young
  • D. L. Longo
  • E. Glatstein
  • P. L. Duffey
  • C. F. Winkler
  • P. H. Wiernik
  • V. T. DevitaJr.
Chapter
Part of the Developments in Oncology book series (DION, volume 32)

Abstract

The development of effective therapies for all stages of Hodgkin’s disease represents one of the most remarkable achievements of modern cancer treatment. What was once considered a uniformly fatal disease has been transformed in the last several decades into one of the most curable malignancies with which we deal. Nevertheless, there are several major areas where improvements in the management of Hodgkin’s disease are needed and several of these areas have been the central focus of ongoing clinical trials at the National Cancer Institute (USA).

Keywords

Early Stage Disease Complete Remission Rate Luteinizing Hormone Release Hormone Combine Modality Approach Radiat Oncol BioI Phys 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kaplan HS (1970). On the natural history, treatment, and prognosis of Hodgkin’s disease. Harvey Lectures 1968–1969, New York: Academic Press.Google Scholar
  2. 2.
    Hellman S, Mauch P, Goodman RL et al. (1978). The place of radiation therapy in the treatment of Hodgkin’s disease. Cancer 42: 971–978.PubMedCrossRefGoogle Scholar
  3. 3.
    Arseneau JC, Sponzo RW, Schnipper LE et al. (1972). Nonlymphomatous malignancies complicating Hodgkin’s disease: Possible association with intensive therapy. N Engl J Med 287: 1119–1122.PubMedCrossRefGoogle Scholar
  4. 4.
    Coleman CN, Williams CJ, Flint A et al. (1977). Hematologic neoplasia in patients treated for Hodgkin’s disease. N Engl J Med 297: 1249–1252.PubMedCrossRefGoogle Scholar
  5. 5.
    Kinzie JJ, Hanks GE, MacLean CJ and Kramer S (1983). Patterns of care study: Hodgkin’s disease relapse rates and adequacy of portals. Cancer 52: 2223–2226.PubMedCrossRefGoogle Scholar
  6. 6.
    DeVita VT, Simon RM, Hubbard SM et al. (1980). Curability of advanced Hodgkin’s disease with chemotherapy. Long-term follow up of MOPP treated patients at the National Cancer Institute. Ann Intern Med 92: 587–595.PubMedGoogle Scholar
  7. 7.
    Canellos GP, Young RC and DeVita VT (1972). Combination chemotherapy for advanced Hodgkin’s disease in relapse following extensive radiotherapy. Clin Pharmacol Ther 13: 750–754.Google Scholar
  8. 8.
    Ziegler JL, Bluming AZ, Faso L et al. (1972). Chemotherapy of childhood Hodgkin’s disease in Uganda. Lancet 2: 679–680.PubMedCrossRefGoogle Scholar
  9. 9.
    Olweny CLM, Katangole Mbidde E, Kiire CL et al. (1978). Childhood Hodgkin’s disease in Uganda: A ten year experience. Cancer 42: 787–792.PubMedCrossRefGoogle Scholar
  10. 10.
    Pavlovsky S, Dupont J, Jimenez E et al. (1984). Randomized study of chemotherapy alone vs. chemotherapy plus radiotherapy in Clinical Stage IA-IIA Hodgkin’s disease. In: Cavalli F, Bonadonna G, and Rozencweig M (Eds). Malignant Lymphomas and Hodgkin’s Disease: Experimental and Therapeutic Advances, pp 337–343. Boston: Martinus Nijhoff.Google Scholar
  11. 11.
    Mauch P, Goodman R and Hellman S (1978). The significance of mediastinal involvement in early stage Hodgkin’s disease. Cancer 42: 1039–1045.PubMedCrossRefGoogle Scholar
  12. 12.
    Velentjas E, Barrett A, McElwan TJ and Peckham MJ (1980). Mediastinal involvement in early stage Hodgkin’s disease. Eur J Cancer 16: 1065–1068.PubMedCrossRefGoogle Scholar
  13. 13.
    Santoro A, Bonadonna G, Bonfante V and Valagussa P (1982). Alternating drug combinations in the treatment of advanced Hodgkin’s disease. N Engl J Med 306: 770–775.PubMedCrossRefGoogle Scholar
  14. 14.
    Kun LE, DeVita VT, Young RC et al. (1976). Treatment of Hodgkin’s disease using intensive chemotherapy followed by irradiation. Int J Radiat Oncol Biol Phys 1: 619–626.PubMedCrossRefGoogle Scholar
  15. 15.
    Longo DL, Young RC and DeVita VT (1982). Chemotherapy for Hodgkin’s disease: The remaining challenges. Cancer Treat Rep 66: 925–936.PubMedGoogle Scholar
  16. 16.
    Santoro A and Bonadonna G (1979). Prolonged disease-free survival in MOPP-resistant Hodgkin’s disease after treatment with adriamycin, bleomycin, vincristine and dacarbazine (ABVD). Cancer Chemother Pharmacol 2: 101–105.PubMedCrossRefGoogle Scholar
  17. 17.
    Bonadonna G, Viviani S, Bonfante V et al. (1984). Alternating chemotherapy with MOPP/ABVD in Hodgkin’s disease. Updated results. Proc Amer Soc Clin Oncol 3: 254.Google Scholar
  18. 18.
    Levi JA, Wiernik PH and Diggs CH (1977). Combination chemotherapy of advanced previously treated Hodgkin’s disease with streptozotocin, CCNU, adriamycin and bleomycin. Med Pediatr Oncol 3: 33–40.PubMedCrossRefGoogle Scholar
  19. 19.
    Diggs CH, Wiernik PH, Kaplan RD et al. (1981). Treatment of Hodgkin’s disease with SCAB-an alternative to MOPP. Cancer 47: 223–248.CrossRefGoogle Scholar
  20. 20.
    Schein PS, O’Connell MJ, Blom J et al. (1974). Clinical antitumor activity and toxicity of streptozotocin. Cancer 34: 993–1000.PubMedCrossRefGoogle Scholar
  21. 21.
    Wheeler GP, Schabel FM and Trader MW (1981). Synergistic antileukemic activity of combinations of two nitrosoureas. Cancer Treat Rep 65: 591–599.PubMedGoogle Scholar

Copyright information

© Martinus Nijhoff Publishers, Boston 1985

Authors and Affiliations

  • R. C. Young
    • 1
  • D. L. Longo
    • 1
  • E. Glatstein
    • 1
  • P. L. Duffey
    • 1
  • C. F. Winkler
    • 1
  • P. H. Wiernik
    • 2
  • V. T. DevitaJr.
  1. 1.National Cancer InstituteBethesdaUSA
  2. 2.Montefiore Medical CenterBronxUSA

Personalised recommendations